Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

Christopher N. Graham, Guy Hechmati, Marwan G. Fakih, Hediyyih N. Knox, Jonas Hjelmgren, Beth Barber, Lee Schwartzberg, Gregory A. Maglinte

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To compare the costs of first-line treatment with panitumumab + FOLFOX in comparison to cetuximab + FOLFIRI among patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC) in the US. Methods: A cost-minimization model was developed assuming similar treatment efficacy between both regimens. The model estimated the costs associated with drug acquisition, treatment administration frequency (every 2 weeks for panitumumab, weekly for cetuximab), and incidence of infusion reactions. Average anti-EGFR doses were calculated from the ASPECCT clinical trial, and average doses of chemotherapy regimens were based on product labels. Using the medical component of the consumer price index, adverse event costs were inflated to 2014 US dollars, and all other costs were reported in 2014 US dollars. The time horizon for the model was based on average first-line progression-free survival of a WT RAS patient, estimated from parametric survival analyses of PRIME clinical trial data. Results: Relative to cetuximab + FOLFIRI in the first-line treatment of WT RAS mCRC, the cost-minimization model demonstrated lower projected drug acquisition, administration, and adverse event costs for patients who received panitumumab + FOLFOX. The overall cost per patient for first-line treatment was $179,219 for panitumumab + FOLFOX vs $202,344 for cetuximab + FOLFIRI, resulting in a per-patient saving of $23,125 (11.4%) in favor of panitumumab + FOLFOX. Conclusions: From a value perspective, the cost-minimization model supports panitumumab + FOLFOX instead of cetuximab + FOLFIRI as the preferred first-line treatment of WT RAS mCRC patients requiring systemic therapy.

Original languageEnglish (US)
Pages (from-to)619-628
Number of pages10
JournalJournal of Medical Economics
Volume18
Issue number8
DOIs
StatePublished - Jan 1 2015

Fingerprint

Colorectal Neoplasms
Costs and Cost Analysis
Therapeutics
Clinical Trials
panitumumab
Cetuximab
Survival Analysis
Pharmaceutical Preparations
Disease-Free Survival
Economics
Drug Therapy
Incidence

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. / Graham, Christopher N.; Hechmati, Guy; Fakih, Marwan G.; Knox, Hediyyih N.; Hjelmgren, Jonas; Barber, Beth; Schwartzberg, Lee; Maglinte, Gregory A.

In: Journal of Medical Economics, Vol. 18, No. 8, 01.01.2015, p. 619-628.

Research output: Contribution to journalArticle

Graham, Christopher N. ; Hechmati, Guy ; Fakih, Marwan G. ; Knox, Hediyyih N. ; Hjelmgren, Jonas ; Barber, Beth ; Schwartzberg, Lee ; Maglinte, Gregory A. / Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. In: Journal of Medical Economics. 2015 ; Vol. 18, No. 8. pp. 619-628.
@article{ada43131816b406a9fc3110d241cfdcf,
title = "Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer",
abstract = "Objective: To compare the costs of first-line treatment with panitumumab + FOLFOX in comparison to cetuximab + FOLFIRI among patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC) in the US. Methods: A cost-minimization model was developed assuming similar treatment efficacy between both regimens. The model estimated the costs associated with drug acquisition, treatment administration frequency (every 2 weeks for panitumumab, weekly for cetuximab), and incidence of infusion reactions. Average anti-EGFR doses were calculated from the ASPECCT clinical trial, and average doses of chemotherapy regimens were based on product labels. Using the medical component of the consumer price index, adverse event costs were inflated to 2014 US dollars, and all other costs were reported in 2014 US dollars. The time horizon for the model was based on average first-line progression-free survival of a WT RAS patient, estimated from parametric survival analyses of PRIME clinical trial data. Results: Relative to cetuximab + FOLFIRI in the first-line treatment of WT RAS mCRC, the cost-minimization model demonstrated lower projected drug acquisition, administration, and adverse event costs for patients who received panitumumab + FOLFOX. The overall cost per patient for first-line treatment was $179,219 for panitumumab + FOLFOX vs $202,344 for cetuximab + FOLFIRI, resulting in a per-patient saving of $23,125 (11.4{\%}) in favor of panitumumab + FOLFOX. Conclusions: From a value perspective, the cost-minimization model supports panitumumab + FOLFOX instead of cetuximab + FOLFIRI as the preferred first-line treatment of WT RAS mCRC patients requiring systemic therapy.",
author = "Graham, {Christopher N.} and Guy Hechmati and Fakih, {Marwan G.} and Knox, {Hediyyih N.} and Jonas Hjelmgren and Beth Barber and Lee Schwartzberg and Maglinte, {Gregory A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.3111/13696998.2015.1035659",
language = "English (US)",
volume = "18",
pages = "619--628",
journal = "Journal of Medical Economics",
issn = "1369-6998",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

AU - Graham, Christopher N.

AU - Hechmati, Guy

AU - Fakih, Marwan G.

AU - Knox, Hediyyih N.

AU - Hjelmgren, Jonas

AU - Barber, Beth

AU - Schwartzberg, Lee

AU - Maglinte, Gregory A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: To compare the costs of first-line treatment with panitumumab + FOLFOX in comparison to cetuximab + FOLFIRI among patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC) in the US. Methods: A cost-minimization model was developed assuming similar treatment efficacy between both regimens. The model estimated the costs associated with drug acquisition, treatment administration frequency (every 2 weeks for panitumumab, weekly for cetuximab), and incidence of infusion reactions. Average anti-EGFR doses were calculated from the ASPECCT clinical trial, and average doses of chemotherapy regimens were based on product labels. Using the medical component of the consumer price index, adverse event costs were inflated to 2014 US dollars, and all other costs were reported in 2014 US dollars. The time horizon for the model was based on average first-line progression-free survival of a WT RAS patient, estimated from parametric survival analyses of PRIME clinical trial data. Results: Relative to cetuximab + FOLFIRI in the first-line treatment of WT RAS mCRC, the cost-minimization model demonstrated lower projected drug acquisition, administration, and adverse event costs for patients who received panitumumab + FOLFOX. The overall cost per patient for first-line treatment was $179,219 for panitumumab + FOLFOX vs $202,344 for cetuximab + FOLFIRI, resulting in a per-patient saving of $23,125 (11.4%) in favor of panitumumab + FOLFOX. Conclusions: From a value perspective, the cost-minimization model supports panitumumab + FOLFOX instead of cetuximab + FOLFIRI as the preferred first-line treatment of WT RAS mCRC patients requiring systemic therapy.

AB - Objective: To compare the costs of first-line treatment with panitumumab + FOLFOX in comparison to cetuximab + FOLFIRI among patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC) in the US. Methods: A cost-minimization model was developed assuming similar treatment efficacy between both regimens. The model estimated the costs associated with drug acquisition, treatment administration frequency (every 2 weeks for panitumumab, weekly for cetuximab), and incidence of infusion reactions. Average anti-EGFR doses were calculated from the ASPECCT clinical trial, and average doses of chemotherapy regimens were based on product labels. Using the medical component of the consumer price index, adverse event costs were inflated to 2014 US dollars, and all other costs were reported in 2014 US dollars. The time horizon for the model was based on average first-line progression-free survival of a WT RAS patient, estimated from parametric survival analyses of PRIME clinical trial data. Results: Relative to cetuximab + FOLFIRI in the first-line treatment of WT RAS mCRC, the cost-minimization model demonstrated lower projected drug acquisition, administration, and adverse event costs for patients who received panitumumab + FOLFOX. The overall cost per patient for first-line treatment was $179,219 for panitumumab + FOLFOX vs $202,344 for cetuximab + FOLFIRI, resulting in a per-patient saving of $23,125 (11.4%) in favor of panitumumab + FOLFOX. Conclusions: From a value perspective, the cost-minimization model supports panitumumab + FOLFOX instead of cetuximab + FOLFIRI as the preferred first-line treatment of WT RAS mCRC patients requiring systemic therapy.

UR - http://www.scopus.com/inward/record.url?scp=84964397359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964397359&partnerID=8YFLogxK

U2 - 10.3111/13696998.2015.1035659

DO - 10.3111/13696998.2015.1035659

M3 - Article

C2 - 25822327

AN - SCOPUS:84964397359

VL - 18

SP - 619

EP - 628

JO - Journal of Medical Economics

JF - Journal of Medical Economics

SN - 1369-6998

IS - 8

ER -